Aktuellt
SENASTE
Redeye provides an initial take following the release of Optomed’s Q3 2024 report. We note that sales and EBIT came in on the soft side, as expected. Moreover, we will release an update where we will dig deeper into the report, with initial expectations of making minor decreases in our sales estimates.
LÄS MER
